Careers in medical devices rarely move in a straight line, and Daniel Wagner's has zigzagged across continents, product categories, and boardrooms for more than twenty years. What ties it together is not a single specialty. It is a habit of showing up early, learning the science, and then figuring out how to turn it into a business.
That habit explains the most telling detail of his current chapter. Before Wagner took a full-time seat at Otolith Labs, the Washington, DC company building a wearable for vertigo, he sat on the outside as an advisor for more than five years. He watched the technology develop. He asked the hard commercial questions. And only when the pieces lined up did he step in, first as Chief Commercial Officer in February 2024 and, per the company's own biography, later as Chief Executive Officer.
It is an unusually patient way to arrive at a job. Most executives chase the title. Wagner chased the problem, and let the title find him.
Two decades, sixty countries
By his own account and the company's, Wagner brings more than two decades of executive experience across the medical device and biotechnology sectors. His work has taken him through more than 60 countries and a dozen healthcare specialties, spanning capital equipment, diagnostics, therapeutics, durable medical equipment, and biologics. That range matters. Selling a complex device in one country teaches you a process; selling it in sixty teaches you that every market is a different conversation.
The resume reads like a tour of the industry's working middle: leadership positions at Olympus Corporation, executive roles at HeartSciences and Signature Biologics, and, most recently before Otolith, the top commercial job at Spark Biomedical. None of these are household names outside the field. All of them share the same core challenge that now defines Wagner's mandate: how do you take a genuinely new medical technology and build the machinery to put it in front of the people who need it?
The hardest kind of launch
Otolith Labs describes its flagship, the OtoBand, as a non-invasive wearable built on a patented approach the company calls non-invasive Vestibular Resonance Therapy, or nVRT. The device has earned an FDA Breakthrough Device Designation, a status reserved for technologies the agency sees as offering something meaningfully new. For a startup, that designation is a beginning, not an ending. Someone still has to build market access, medical affairs, sales operations, and marketing from close to nothing.
That someone is Wagner. Since joining, he has been charged with developing the company's go-to-market strategy and standing up the operational infrastructure to support a commercial launch. It is the least glamorous and most decisive work in medtech. A breakthrough device with no plan to reach patients is a science project. A plan without conviction behind it is a slide deck. Wagner's whole career has been about closing that gap.
The degree of difficulty here is real. There is no direct competitor to copy, no established playbook to borrow, no reference product to price against. When you commercialize a first-of-its-kind wearable, you write the map as you walk it. That is exactly the situation Wagner has spent twenty years preparing for, in markets where the rules were never quite the same twice.
Why the patience matters
The five-year advisory run is the thread worth pulling. It signals a leader who values understanding over speed, who would rather earn conviction slowly than manufacture it in a pitch. In a startup culture that prizes velocity, Wagner's arc is a quiet argument for the opposite virtue. He knew the technology before he sold it. He knew the team before he led it.
Otolith Labs raised a $20 million Series A led by Morningside Ventures to fund its work, part of a broader capital base that has given the company room to move from clinical development toward the market. The money buys time. Wagner's job is to make sure the time produces a commercial engine, not just a longer runway.
He tends to describe his strengths in operator's terms: leading corporate growth initiatives, defining business operations, integrating strategy with data-driven decision-making, scaling across global markets. It is the vocabulary of someone more comfortable building systems than chasing spotlights. In a field crowded with visionaries, Otolith Labs hired a builder, and then made him the boss.
The story is still being written. The OtoBand's commercial fate will be decided in the unglamorous details of reimbursement, distribution, and adoption, the exact terrain Wagner has walked for two decades. If it works, the through-line of his career will finally converge on a single object small enough to wear on your head. If there is a lesson in his path so far, it is that the right person for a hard launch is often the one who waited the longest to say yes.